RxDoctor Payments DataLook up a doctor →

Jan Davis, APRN

Acute Care · Ogden, UTNPI 1821171786

Payments from drug & device makers

$90,000in general payments, 2019–2025

Across 540 payments — averaging $166.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$34K
  • AstraZeneca$24K
  • Karyopharm Therapeutics Inc.$9K
  • GSK$5K
  • Lilly USA, LLC$3K
  • Astrazeneca UK Limited$3K
  • plus $12K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.77$34,160
AstraZeneca(2 entities)71$23,654
Karyopharm Therapeutics Inc.18$9,311
GSK16$4,619
Lilly USA, LLC14$2,987
Astrazeneca UK Limited12$2,965
Novartis21$2,263
Accord Healthcare, Inc.1$1,657
Astellas Pharma US Inc14$656
Johnson & Johnson19$625
Sanofi15$528
Beigene USA, Inc.7$456
Genentech USA, Inc.14$433
Seagen Inc.17$397
Coherus Oncology, Inc.1$366
Incyte Corporation9$360
Bristol Myers Squibb22$351
AbbVie13$350
E.r. Squibb & Sons, L.L.C.15$330
Merck16$314
Pharmacyclics LLC, An Abbvie Company8$290
Pfizer15$251
Amneal Pharmaceuticals LLC11$245
EMD Serono, Inc.11$242
Eisai Inc.10$205
Sumitomo Pharma America, Inc.12$194
Genmab U.S., Inc.7$170
Amgen6$150
Regeneron Healthcare Solutions, Inc.5$145
Boehringer Ingelheim6$144
Sanofi-aventis U.S. LLC1$100
Myriad Women's Health, Inc.1$84
G1 Therapeutics, Inc.3$78
Array Biopharma Inc4$68
Deciphera Pharmaceuticals Inc.4$61
Jazz Pharmaceuticals Inc.4$61
Tersera Therapeutics LLC3$58
Pharming Healthcare, Inc.2$47
Servier Pharmaceuticals LLC2$46
Bayer3$45
Pharmacosmos Therapeutics Inc.2$43
Pharmaessentia USA Corporation2$38
Myovant Sciences Inc.2$34
Puma Biotechnology, Inc.2$33
Tempus AI, Inc2$33
Morphosys, US Inc.2$31
Organon2$26
Sobi, Inc1$25
Ipsen Biopharmaceuticals, Inc1$25
Iovance Biotherapeutics, Inc.1$23
Dova Pharmaceuticals1$22
Myriad Genetic Laboratories, Inc.1$20
EUSA Pharma (US) LLC1$19
Azurity Pharmaceuticals, Inc.1$19
Helsinn Therapeutics (U.S.), Inc.1$19
Octapharma USA, Inc.1$18
Foundation Medicine, Inc.1$17
Exelixis Inc.1$17
Stemline Therapeutics Inc.1$16
Blueprint Medicines Corporation1$14

How this compares

$90,000 in reported general payments places this provider in the 95th percentile of 119 acute care providers in Utah.

See all acute care providers in Utah

Medicare billing

Part B allowed, 2024
$638,004
Medicare patients
323
Services billed
35,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →